A randomized phase II study on the optimization of immunotherapy in squamous carcinoma of the head and neck (OPTIM)
Latest Information Update: 22 Nov 2022
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Docetaxel
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms OPTIM
- 17 Nov 2022 Status changed from discontinued to completed.
- 13 Sep 2022 Status has been changed to discontinued, as per Results presented at the 47th European Society for Medical Oncology Congress
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress